Cited by 7,449Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Open access

Shepherd, James, Cobbe, Stuart M., Ford, Ian, Isles, Christopher G., Lorimer, A. Ross, Macfarlane, Peter W., McKillop, James H., Packard, Christopher J.·1995·New England Journal of Medicine

DOI 10.1056/nejm199511163332001

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Lowering the blood cholesterol level may reduce the risk of coronary heart disease. This double-blind study was designed to determine whether the administration of pravastatin to men with hypercholesterolemia and no history of myocardial infarction reduced the combined incidence of nonfatal myocardial infarction and death from coronary heart disease. METHODS: We randomly assigned 6595 men, 45 to 64 years of age, with a mean (+/- SD) plasma cholesterol level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive pravastatin (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national death registry were used to determine the clinical end points. RESULTS: Pravastatin lowered plasma cholesterol levels by 20 percent and low-density-lipoprotein cholesterol levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal myocardial infarction or death from coronary heart disease) in the placebo group, and 174 in the pravastatin group (relative reduction in risk with pravastatin, 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal myocardial infarctions (31 percent reduction, P < 0.001), death from coronary heart disease (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and death from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the pravastatin group. We observed a 22 percent reduction in the risk of death from any cause in the pravastatin group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with pravastatin significantly reduced the incidence of myocardial infarction and death from cardiovascular causes without adversely affecting the risk of death from noncardiovascular causes in men with moderate hypercholesterolemia and no history of myocardial infarction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199511163332001

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.
(1985) · BMJ · doi:10.1136/bmj.291.6488.97 · Cited by 1,491
Modelling Survival Data in Medical Research
Collett, D. (1994) · Springer eBooks · doi:10.1007/978-1-4899-3115-3 · Cited by 1,064
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.
Oliver, M., Heady, J., Morris, J. N., Cooper, J., Geizerova, H., Gyárfás, I., Green, K., Strasser, T., Macfie, W. G., Scott, E., et al. (1978) · Heart · doi:10.1136/hrt.40.10.1069 · Cited by 1,047
Modelling Survival Data in Medical Research.
McLachlan, G. J., & Collett, D. (1994) · Biometrics · doi:10.2307/2533471 · Cited by 1,023
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Jukema, J., Bruschke, A. V., van Boven, A. J., Reiber, J., Bal, E., Zwinderman, A., Jansen, H., Boerma, G., van Rappard, F. M., & Kong, L. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 911
Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J. L., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 865

Show all 26 references

Research works printed but not linked: 4

10.1001/jama.251.3.351 · DOI · Paper page
1994, Lancet, 344, 1383
1992, Nutr Metab Cardiovasc Dis, 2, 113
Macfarlane PW, 1990, Eur Heart J, 11, 411

Sorted by citations

Items 301–400 of 1,060

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia
Grundy, S. M. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.10.001 · Cited by 353
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Inhibition of Geranylgeranylation Reduces Angiotensin II-Mediated Free Radical Production in Vascular Smooth Muscle Cells: Involvement of Angiotensin AT1 Receptor Expression and Rac1 GTPase
Waßmann, S., Laufs, U., Bäumer, A. T., Müller, K., Konkol, C., Sauer, H., Böhm, M., & Nickenig, G. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.3.646 · Cited by 340
Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women
Mosca, L. J., Appel, L. J., Benjamin, E. J., Berra, K. A., Chandra‐Strobos, N., Fabunmi, R. P., Grady, D. G., Haan, C. K., Hayes, S. N., Judelson, D. R., et al. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000114834.85476.81 · Cited by 342
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials
Mills, E. J., WU, P., Chong, G., Ghement, I., Singh, S., Akl, E. A., Eyawo, O., Guyatt, G., Berwanger, O., & Briel, M. (2011) · QJM · doi:10.1093/qjmed/hcq165 · Cited by 338
Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study
Holdaas, H., Fellström, B., Cole, E., Nyberg, G., OLSSON, A. G., Pedersen, T. R., Madsen, S., Grönhagen‐Riska, C., Neumayer, H. ‐., Maes, B., et al. (2005) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01105.x · Cited by 346
Associations between C-reactive protein, coronary artery calcium, and cardiovascular events: implications for the JUPITER population from MESA, a population-based cohort study
Blaha, M. J., Budoff, M. J., DeFilippis, A. P., Blankstein, R., Rivera, J. J., Agatston, A. S., O’Leary, D. H., Lima, J. A. C., Blumenthal, R. S., & Nasir, K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60784-8 · Cited by 342
Infant Feeding and Blood Cholesterol: A Study in Adolescents and a Systematic Review
Owen, C. G., Whincup, P. H., Odoki, K., Gilg, J. A., & Cook, D. G. (2002) · PEDIATRICS · doi:10.1542/peds.110.3.597 · Cited by 340
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
(2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30156-5 · Cited by 338
Pravastatin Therapy and the Risk of Stroke
White, H. D., Simes, R. J., Anderson, N. E., Hankey, G. J., Watson, J. D. G., Hunt, D., Colquhoun, D. M., Glasziou, P., MacMahon, S. W., Kirby, A. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200008033430502 · Cited by 335
Meditation and Cardiovascular Risk Reduction: A Scientific Statement From the American Heart Association
Levine, G. N., Lange, R. A., Bairey‐Merz, C. N., Davidson, R. J., Jamerson, K., Mehta, P. K., Michos, E. D., Norris, K., Ray, I. B., Saban, K. L., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.002218 · Cited by 330
Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 331
Rho/Rho-kinase mediated signaling in physiology and pathophysiology
Wettschureck, N., & Offermanns, S. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0370-2 · Cited by 338
Association of apo B lipoproteins with arterial proteoglycans: Pathological significance and molecular basis
Camejo, G., Hurt‐Camejo, E., Wiklund, O., & Bondjers, G. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00107-5 · Cited by 334
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 336
Non-lipid-related effects of statins
Bellosta, S., Fed, N., Bernini, F., Paoletti, R., & Corsini, A. (2000) · Annals of Medicine · doi:10.3109/07853890008998823 · Cited by 338
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S)
Strandberg, T. E., Pyörälà, K., Cook, T. J., Wilhelmsen, L., Færgeman, O., Þorgeirsson, G., Pedersen, T. R., & KJEKSHUS, J. K. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16936-5 · Cited by 329
Cholesterol in Childhood
Committee on Nutrition (1998) · PEDIATRICS · doi:10.1542/peds.101.1.141 · Cited by 330
Coronary Artery Disease: From Mechanism to Clinical Practice
Shao, C., Wang, J., Tian, J., & Tang, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_1 · Cited by 368
An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report
Grundy, S. M., Arai, H., Barter, P. J., Bersot, T. P., Betteridge, D. J., Carmena, R., Cuevas, A. M., Davidson, M. H., Genest, J. J., Kesäniemi, Y. A., et al. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.12.005 · Cited by 334
Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in Mice
Amin‐Hanjani, S., Stagliano, N. E., Yamada, M., Huang, P. L., Liao, J. K., & Moskowitz, M. A. (2001) · Stroke · doi:10.1161/01.str.32.4.980 · Cited by 323
Simvastatin Preserves the Ischemic-Reperfused Myocardium in Normocholesterolemic Rat Hearts
Lefer, A. M., Campbell, B., Shin, Y.-K., Scalia, R. G., Hayward, R., & Lefer, D. J. (1999) · Circulation · doi:10.1161/01.cir.100.2.178 · Cited by 327
Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
van Heek, M., Farley, C., Compton, D. S., Hoos, L. M., Alton, K. B., Sybertz, E. J., & Davis, H. R. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703235 · Cited by 322
Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness
Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., & Berglund, G. (2001) · Circulation · doi:10.1161/01.cir.103.13.1721 · Cited by 324
Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidemia
Mora, S., Glynn, R. J., Hsia, J. A., MacFadyen, J. G., Genest, J. J., & Ridker, P. M. (2010) · Circulation · doi:10.1161/circulationaha.109.906479 · Cited by 328
Suboptimal statin adherence and discontinuation in primary and secondary prevention populations
Ellis, J. J., Erickson, S. R., Stevenson, J. G., Bernstein, S. J., Stiles, R. A., & Fendrick, A. M. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30516.x · Cited by 320
A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma.
McKay, A., Leung, B. P., McInnes, I. B., Thomson, N. C., & Liew, F. Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2903 · Cited by 309
Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing
Bjornsson, E. S., Jacobsen, E. I., & Kalaitzakis, E. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.07.023 · Cited by 320
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316
Cardiovascular risk factors and confounders among nondrinking and moderate-drinking U.S. adults
Naimi, T. S., Brown, D. W., Brewer, R. D., Giles, W. H., Mensah, G. A., Serdula, M. K., Mokdad, A. H., Hungerford, D. W., Lando, J. F., Naimi, S., et al. (2005) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2005.01.011 · Cited by 322
Clinical Outcomes and Cost-Effectiveness of Strategies for Managing People at High Risk for Diabetes
Eddy, D. M., Schlessinger, L., & Kahn, R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00006 · Cited by 318
Progression of Coronary Artery Calcium and Risk of First Myocardial Infarction in Patients Receiving Cholesterol-Lowering Therapy
Raggi, P., Callister, T. Q., & Shaw, L. J. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000127024.40516.ef · Cited by 318
C-Reactive Protein and Outcome After Ischemic Stroke
Muir, K. W., Weir, C. J., Alwan, W. H., Squire, I. B., & Lees, K. R. (1999) · Stroke · doi:10.1161/01.str.30.5.981 · Cited by 316
HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study
Després, J., Lemieux, I., Dagenais, G. R., Cantin, B., & Lamarche, B. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00603-1 · Cited by 316
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Increase Fibrinolytic Activity in Rat Aortic Endothelial Cells
Essig, M., Nguyen, G., Prié, D., Escoubet, B., Sraer, J., & Friedlander, G. (1998) · Circulation Research · doi:10.1161/01.res.83.7.683 · Cited by 316
HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION
KOBASHIGAWA, J. A., & Kasiske, B. L. (1997) · Transplantation · doi:10.1097/00007890-199702150-00001 · Cited by 314
Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I., Muniyappa, R., Francisco, R., & Sowers, J. R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8412 · Cited by 317
Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose
Keech, A., Colquhoun, D., Best, J., Kirby, A., Simes, R. J., Hunt, D., Hague, W., Beller, E., Arulchelvam, M., Baker, J., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2713 · Cited by 313
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
Aronow, H. D., Topol, E. J., Roe, M. T., Houghtaling, P. L., Wolski, K. E., Lincoff, A. M., Harrington, R. A., Califf, R. M., Ohman, E. M., Kleiman, N. S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04257-4 · Cited by 308
Stroke, Statins, and Cholesterol
Blauw, G. J., Lagaay, A. M., Smelt, A. H. M., & Westendorp, R. G. J. (1997) · Stroke · doi:10.1161/01.str.28.5.946 · Cited by 313
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies
Bays, H. E., Moore, P. B., Drehobl, M., Rosenblatt, S., Toth, P. D., Dujovne, C. A., Knopp, R. H., Lipka, L., LeBeaut, A., Yang, B., et al. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80102-8 · Cited by 314
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
Grundy, S. M., Vega, G. L., Yuan, Z., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.012 · Cited by 309
Colesevelam Hydrochloride (Cholestagel): A New, Potent Bile Acid Sequestrant Associated With a Low Incidence of Gastrointestinal Side Effects
Davidson, M. H., Dillon, M. A., Gordon, B., Jones, P., Samuels, J., Weiss, S., Isaacsohn, J., Toth, P., & Burke, S. K. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.16.1893 · Cited by 307
Statins in the primary prevention of cardiovascular disease
Reiner, Ž. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.80 · Cited by 314
Dyslipidaemia
Durrington, P. N. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14234-1 · Cited by 316
A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality
Wadhera, R. K., Steen, D. L., Khan, I., Giugliano, R. P., & Foody, J. M. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.11.010 · Cited by 306
Canadian Cardiovascular Society position statement – Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease
McPherson, R., Frohlich, J. J., Fodor, G. J., & Genest, J. J. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70310-5 · Cited by 306
Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial
Lewis, J. H., Mortensen, M. E., Zweig, S., Fusco, M. J., Medoff, J. R., & Belder, R. (2007) · Hepatology · doi:10.1002/hep.21848 · Cited by 248
Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia
de Jongh, S., Ose, L., Szamosi, T., Gagné, C., Lambert, M. A., Scott, R. S., Perron, P., Dobbelaere, D., Saborio, M., Tuohy, M. B., et al. (2002) · Circulation · doi:10.1161/01.cir.0000035247.42888.82 · Cited by 308
Statins for the primary prevention of cardiovascular disease
Taylor, F. C., Ward, K. J., Moore, T. H., Burke, M., Smith, G. D., Casas, J. P., & Ebrahim, S. B. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 315
Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005
Ridker, P. M., & Torres, J. (2006) · JAMA · doi:10.1001/jama.295.19.2270 · Cited by 300
Meta‐analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes
Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02060.x · Cited by 303
Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol
Liao, J. K. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.009 · Cited by 310
Numbers needed to treat derived from meta-analyses---sometimes informative, usually misleading
Smeeth, L. L., Haines, A., & Ebrahim, S. B. J. (1999) · BMJ · doi:10.1136/bmj.318.7197.1548 · Cited by 299
Sudden Cardiac Death: Exploring the Limits of Our Knowledge
Myerburg, R. J. (2001) · Journal of Cardiovascular Electrophysiology · doi:10.1046/j.1540-8167.2001.00369.x · Cited by 300
Dietary fats and coronary heart disease
Willett, W. C. (2012) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02553.x · Cited by 314
Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences
Rauch, U., Osende, J. I., Fuster, V., Badimón, J. J., Fayad, Z. A., & Chesebro, J. H. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-3-200102060-00014 · Cited by 300
Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease
Young‐Xu, Y., Jabbour, S., Goldberg, R. J., Blatt, C. M., Graboys, T. B., Bilchik, B. Z., & Ravid, S. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.040 · Cited by 290
Exploiting the Vascular Protective Effects of High-Density Lipoprotein and its Apolipoproteins
Shah, P. K., Kaul, S., Nilsson, J. Å., & Cercek, B. (2001) · Circulation · doi:10.1161/hc4501.098468 · Cited by 298
Ezetimibe therapy: mechanism of action and clinical update
Toth, P. P., Phan, B. A. P., & Dayspring, T. D. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33664 · Cited by 312
Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Zhou, Q., & Liao, J. K. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315684 · Cited by 301
Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators
Gervois, P., Torra, I. P., Fruchart, J.-C., & Staels, B. (2000) · cclm · doi:10.1515/cclm.2000.002 · Cited by 249
Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study
Li, W., Wang, J., Thompson, P., Wong, S., Struthers, A. D., & MacDonald, T. M. (2002) · Heart · doi:10.1136/heart.88.3.229 · Cited by 293
The genetic basis of variability in drug responses
Roden, D. M., & George, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 297
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control
Nakata, M., Nagasaka, S., Kusaka, I., Matsuoka, H., Ishibashi, S., & Yada, T. (2006) · Diabetologia · doi:10.1007/s00125-006-0269-5 · Cited by 296
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
Seliger, S. L., Weiss, N. S., Gillen, D. L., Kestenbaum, B. R., Ball, A., Sherrard, D. J., & Stehman‐Breen, C. O. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00109.x · Cited by 292
Atorvastatin
Lea, A. P., & McTavish, D. (1997) · Drugs · doi:10.2165/00003495-199753050-00011 · Cited by 292
The Role of Statins in Cancer Therapy
Hindler, K., Cleeland, C. S., Rivera, E., & Collard, C. D. (2006) · The Oncologist · doi:10.1634/theoncologist.11-3-306 · Cited by 290
Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study
Menotti, A. (2000) · European Heart Journal · doi:10.1053/euhj.1999.1864 · Cited by 291
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
Chou, R., Cantor, A., Dana, T., Wagner, J., Ahmed, A. Y., Fu, R., & Ferencik, M. (2022) · JAMA · doi:10.1001/jama.2022.12138 · Cited by 287
Increasing Burden of Cardiovascular Disease
Hennekens, C. H. (1998) · Circulation · doi:10.1161/01.cir.97.11.1095 · Cited by 289
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
De Vera, M. A., Bhole, V., Burns, L. C., & Lacaille, D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12339 · Cited by 289
A Randomized Trial of the Effect of Community Pharmacist Intervention on Cholesterol Risk Management The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP)
Tsuyuki, R. T. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.10.1149 · Cited by 288
Improved Postoperative Outcomes Associated with Preoperative Statin Therapy
Hindler, K., Shaw, A., Samuels, J., Fulton, S., Collard, C. D., Riedel, B., & Warltier, D. C. (2006) · Anesthesiology · doi:10.1097/00000542-200612000-00027 · Cited by 288
Current overview of statin-induced myopathy
Rosenson, R. S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.033 · Cited by 285
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics
Koren, M. J., & Hunninghake, D. B. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.07.053 · Cited by 292
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, . (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 290
Antioxidant Activity and Phenolic Compositions of Lentil (Lens culinaris var. Morton) Extract and Its Fractions
Zou, Y., Chang, S. K. C., Gu, Y., & Qian, S. Y. (2011) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf104640k · Cited by 285
Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)
Graham, I. D., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277984.31558.c4 · Cited by 299
Safety and Tolerability of Cholesterol Lowering With Simvastatin During 5 Years in the Scandinavian Simvastatin Survival Study
Pedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440170097011 · Cited by 283
Surrogate Markers for Cardiovascular Disease
Cohn, J. N., Quyyumi, A. A., Hollenberg, N. K., & Jamerson, K. (2004) · Circulation · doi:10.1161/01.cir.0000133442.99186.39 · Cited by 288
Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease
Abdullah, S. M., DeFina, L. F., Leonard, D. S., Barlow, C. E., Radford, N. B., Willis, B. L., Rohatgi, A. K., McGuire, D. K., de Lemos, J. A., Grundy, S. M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034273 · Cited by 279
Pathophysiology and treatment of atherosclerosis
Bergheanu, S. C., Bodde, M. C., & Jukema, J. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-0959-2 · Cited by 299
Role of Oxidized LDL in Atherosclerosis
Kita, T., Kume, N., Minami, M., Hayashida, K., Murayama, T., Sano, H., Moriwaki, H., Kataoka, H., Nishi, E., Horiuchi, H., et al. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03941.x · Cited by 284
Effect of Vitamin E and Beta Carotene on the Incidence of Primary Nonfatal Myocardial Infarction and Fatal Coronary Heart Disease
Virtamo, J. R. K., Rapola, J., Ripatti, S., Heinonen, O. P., Taylor, P. R., Albanes, D., & Huttunen, J. K. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.668 · Cited by 274
HMG-CoA Reductase Inhibitors and Myotoxicity
Ucar, M., Mjörndal, T., & Dahlqvist, R. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00003 · Cited by 279
Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients With Essential Hypertension and Primary Hypercholesterolemia
Glorioso, N., Troffa, C., Filigheddu, F., Dettori, F., Soro, A., Parpaglia, P. P., Collatina, S., & Pahor, M. (1999) · Hypertension · doi:10.1161/01.hyp.34.6.1281 · Cited by 278
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
Institute of Medicine (2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 274
Statin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 275
Role of endothelial dysfunction in insulin resistance
Hsueh, W. A., & Quiñones, M. J. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00611-8 · Cited by 271
Reduction of Stroke Events With Pravastatin
Byington, R. P., Davis, B. R., Plehn, J. F., White, H. D., Baker, J., Cobbe, S. M., & Shepherd, J. (2001) · Circulation · doi:10.1161/01.cir.103.3.387 · Cited by 275
European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
Backer, G. D., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 273
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 281
III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia
Santos, R. D. (2001) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2001001500001 · Cited by 264
Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery
Katsimaglis, G., Danias, P. G., Danias, P. G., O'Neil-Callahan, K., Ryan, J. W., Mosby, C., Danias, P. G., Katsimaglis, G., Ioannidis, J. P. A., Ioannidis, J. P. A., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.048 · Cited by 272
Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol lowering
Pedersen, T. R., Wilhelmsen, L., Færgeman, O., Strandberg, T. E., Þorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T. J., Haghfelt, T. H., et al. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00910-3 · Cited by 274
Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003–2006
Toth, P. P., Potter, D. M., & Ming, E. E. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.05.002 · Cited by 272
Statins and risk of polyneuropathy
Gaist, D., Jeppesen, U., Andersen, M. T., Rodríguez, L. A. G., Hallas, J., & Sindrup, S. H. (2002) · Neurology · doi:10.1212/wnl.58.9.1333 · Cited by 270
Efficacy and Safety of Lovastatin in Adolescent Males With Heterozygous Familial Hypercholesterolemia
Stein, E. A., Illingworth, D. R., Kwiterovich, P. O., Liacouras, C. A., Siimes, M. A., Jacobson, M. S., Brewster, T. G., Hopkins, P. N., Davidson, M. H., Graham, K. J., et al. (1999) · JAMA · doi:10.1001/jama.281.2.137 · Cited by 272
Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising Future
van Raalte, D. H., Li, M., Pritchard, P. H., & Wasan, K. M. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041444.06122.8d · Cited by 270

Authors: Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J.
Affiliations: Glasgow Royal Infirmary (GB)
University of Glasgow (GB)
NHS Dumfries and Galloway (GB)
ORCID: Ford, Ian
Macfarlane, Peter W.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1995-11-16
Volume: 333
Issue: 20
Pages: 1301-1308
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199511163332001
OpenAlex: W2155598961
Semantic Scholar: 1aa5f64bbe1d0c4c74fc3de7c89ac2dffb48630a
Cited by: 7,449
References: 26
Citations by year: 2026: 31 · 2025: 33 · 2024: 56 · 2023: 54 · 2022: 66 · 2021: 72 · 2020: 95 · 2019: 90 · 2018: 108 · 2017: 121 · 2016: 157 · 2015: 137 · 2014: 177 · 2013: 215 · 2012: 197
FWCI: 344.87
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: pravastatin, hypercholesterolemia, coronary heart disease prevention, statins, LDL cholesterol lowering, nonfatal myocardial infarction, cardiovascular mortality, men, cholesterol-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Disease, Double-Blind Method, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Neoplasms, Risk, Incidence, Survival Analysis, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks